OTSUKA PHARMACEUTICAL CO., LTD.
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Public, Subsidiary
- Established
- 1964-01-01
- Employees
- 101
- Market Cap
- -
- Website
- http://www.otsuka.co.jp
A Multicenter, Placebo-controlled, Double-blind Investigative Extension Trial of the Safety and Efficacy of Aripiprazole in the Treatment of Patients With Bipolar Disorder Experiencing a Manic or Mixed Episode
- First Posted Date
- 2008-02-01
- Last Posted Date
- 2014-02-12
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 99
- Registration Number
- NCT00606177
A Study of OPC-41061 in Subjects With Cardiac-induced Edema (Congestive Heart Failure)
Phase 3
Completed
- Conditions
- Cardiac Edema
- Interventions
- Drug: OPC-41061 （Tolvaptan)
- First Posted Date
- 2007-10-16
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 52
- Registration Number
- NCT00544869
A Placebo-controlled Study for SPM 962 in Early Parkinson's Disease Patients
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT00537485
A Clinical Pharmacological Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Phase 3
Completed
- Conditions
- Cardiac Edema
- Interventions
- Drug: OPC-41061(Tolvaptan)Drug: Placebo
- First Posted Date
- 2007-09-05
- Last Posted Date
- 2013-12-25
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 20
- Registration Number
- NCT00525265
A Phase II Study of a Continuous Hepatic Arterial Infusion Combination Therapy With OPC-18 and 5-FU in Patients With Highly Advanced Hepatocellular Carcinoma
- First Posted Date
- 2007-09-03
- Last Posted Date
- 2015-10-15
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT00524498
Dose-ranging Trial of OPC-249 Powder Inhalation in Patients With Pain Due to Osteoporosis
- First Posted Date
- 2007-07-20
- Last Posted Date
- 2014-01-30
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 101
- Registration Number
- NCT00504426
A Dose-defining Study of OPC-41061 in Treatment of Hepatic Edema
Phase 2
Completed
- Conditions
- Cirrhosis
- Interventions
- Drug: OPC-41061 15mgDrug: OPC-41061 placeboDrug: OPC-41061 7.5mgDrug: OPC-41601 30mg
- First Posted Date
- 2007-05-28
- Last Posted Date
- 2014-03-14
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 104
- Registration Number
- NCT00479336
Late Phase 2 Study of OPC-12759 Ophthalmic Suspension
Phase 2
Completed
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: placeboDrug: 1% OPC-12759 ophthalmic suspensionDrug: 2% OPC-12759 ophthalmic suspension
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2013-06-13
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 308
- Registration Number
- NCT00475319
An Exploratory Study of Rebamipide in Patients With Active Ulcerative Colitis
- First Posted Date
- 2007-04-20
- Last Posted Date
- 2021-07-20
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 124
- Registration Number
- NCT00463151
A Double-blind, Placebo-controlled Study of OPC-41061 in the Treatment of Cardiac Edema (Congestive Heart Failure)
Phase 3
Completed
- Conditions
- Edema, Cardiac
- Interventions
- Drug: OPC-41061(Tolvaptan)
- First Posted Date
- 2007-04-19
- Last Posted Date
- 2014-02-04
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 110
- Registration Number
- NCT00462670
© Copyright 2025. All Rights Reserved by MedPath